Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 20.28 0.17 (0.85%) Market Cap: 1.72 Bil Enterprise Value: 1.28 Bil PE Ratio: 0 PB Ratio: 3.50 GF Score: 53/100

Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 06:30PM GMT
Release Date Price: $25.62 (-1.16%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the Wednesday morning of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at J.P. Morgan. I'm joined by my colleagues, Malcolm Kuno and Priyanka Grover. Our next presenting company is Syndax and presenting on the behalf of the company, we have CEO, Michael Metzger.

Michael A. Metzger
Syndax Pharmaceuticals, Inc. - CEO & Director

Thank you, Anupam. I want to first start off by saying this is our first time presenting as a company at JPMorgan. So we're thrilled to be here. Appreciate the opportunity to do so. Also appreciate the initiation report from Anupam to start '23. It was a great way to begin the year.

So with that, this is our forward-looking statements. Of course, I'll be making forward-looking statements today. This is posted on our website. I encourage you to take a look at it. It's also in our presentation.

So 2023 is shaping up to be a, what I would call, a very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot